2C or Not 2C: Phenethylamine Designer Drug Review
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
New groups of synthetic "designer drugs" have increased in popularity over the past several years. These products mimic the euphoric effects of other well-known illicit drugs but are advertised as "legal" highs and are sold over the internet, at raves and night clubs, and in head shops. The 2C series drugs are ring-substituted phenethylamines that belong to a group of designer agents similar in structure to 3,4-methylenedioxy-N-methylamphetamine (MDMA, Ecstasy). Understanding the pharmacology and toxicology of these agents is essential in order to provide the best medical care for these patients. This review focuses on the pharmacology, pharmacokinetics, clinical effects, and treatment of 2C drug intoxication based on available published literature. Multiple names under which 2C drugs are sold were identified and tabulated. Common features identified in patients intoxicated with 2Cs included hallucinations, agitation, aggression, violence, dysphoria, hypertension, tachycardia, seizures, and hyperthermia. Patients may exhibit sympathomimetic symptoms or symptoms consistent with serotonin toxicity, but an excited delirium presentation seems to be consistent amongst deaths attributed to 2C drugs; at least five deaths have been reported in the literature in patients intoxicated with 2C drugs. 2C drugs are a group of designer intoxicants, many of which are marketed as legal, but may carry risks that consumers are unaware of. These drugs may be characterized by either serotonergic toxicity or a sympathomimetic toxidrome, but a presentation consistent with excited delirium is consistent amongst the reported 2C-related deaths. Treatment of 2C intoxication is primarily supportive, but immediate action is required in the context of excited delirium, hyperthermia, and seizure activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shulgin, A. T., & Shulgin, A. (1991) · Cited by 668
Battaglia, J., Moss, S., Rush, J., Kang, J., Mendoza, R., Leedom, L., Dubin, W., McGlynn, C., & Goodman, L. (1997) · The American Journal of Emergency Medicine · doi:10.1016/s0735-6757(97)90119-4 · Cited by 350 · cited 1×
“showed superior efficacy with a combination of haloperidol and lorazapam as compared to either drug alone for psychotic agitation [49].”
BackgroundThe effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.075 · Cited by 279 · cited 1×
“Limited information suggests that 2C drugs also inhibit reuptake of monoamines including norepinephrine, dopamine, and serotonin [24].”
BackgroundPurchasing 'legal highs' on the Internet--is there consistency in what you get?
Davies, S., Wood, D. M., Smith, G., Button, J., Ramsey, J., Archer, R., Holt, D. W., & Dargan, P. I. (2010) · QJM · doi:10.1093/qjmed/hcq056 · Cited by 212
Alexander, J., Tharyan, P., Adams, C., John, T., Mol, C., & Philip, J. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.1.63 · Cited by 177
Martel, M., Sterzinger, A., Miner, J., Clinton, J., & Biros, M. (2005) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2005.tb01492.x · Cited by 170
Wilson, J. M., Shannak, K., Kish, S. J., Levey, A. I., Bergeron, C., Deck, J., Kalasinsky, K., Ang, L., Peretti, F., Adams, V. I., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400312 · Cited by 170
Dopamine transport function is elevated in cocaine users
Mash, D. C., Pablo, J., Ouyang, Q., Hearn, W. L., & Izenwasser, S. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00820.x · Cited by 167 · cited 1×
“The pathophysiology of excited delirium is believed to primarily involve dopamine and has been previously described with cocaine use [27].”
BackgroundSchmauss, C., Haroutunian, V, Davis, K. L., & Davidson, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.8942 · Cited by 162
Nobay, F., Simon, B., Levitt, M. A., & Dresden, G. M. (2004) · Academic Emergency Medicine · doi:10.1197/j.aem.2003.06.015 · Cited by 148
Metabolism of Designer Drugs of Abuse: An Updated Review
Meyer, M. R., & Maurer, H. H. (2010) · Current Drug Metabolism · doi:10.2174/138920010791526042 · Cited by 125 · cited 3×
“Reported effects of 2Cs are a combination of hallucinogenic and stimulating effects [20].”
BackgroundMonte, A. P., Marona-Lewicka, D., Parker, M. A., Wainscott, D. B., Nelson, D. L., & Nichols, D. E. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960199j · Cited by 106
“Research Chemicals”: Tryptamine and Phenethylamine Use Among High-Risk Youth
Sanders, B., Lankenau, S. E., Bloom, J. J., & Hathazi, D. (2008) · Substance Use & Misuse · doi:10.1080/00952990701202970 · Cited by 95
Carmo, H., Hengstler, J. G., de Boer, D., Ringel, M. T., Remião, F., Carvalho, F. D., Fernandes, E. G. R., dos Reys, L. A., Oesch, F., & Bastos, M. D. L. (2004) · Toxicology · doi:10.1016/j.tox.2004.07.004 · Cited by 86 · cited 2×
“The compound is deaminated and then oxidated to either the corresponding acid or base [18, 20, 21].”
BackgroundStephens, B. G., Jentzen, J. M., Karch, S., Mash, D. C., & Wetli, C. V. (2004) · American Journal of Forensic Medicine & Pathology · doi:10.1097/01.paf.0000118960.58334.a9 · Cited by 84
Toxin-Induced Hyperthermic Syndromes
Rusyniak, D. E., & Sprague, J. E. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2005.06.002 · Cited by 83
Brain Dopamine Transporter Messenger RNA and Binding Sites in Cocaine Users: A Postmortem Study
Little, K. Y., McLaughlin, D. P., Zhang, L., McFinton, P. R., Dalack, G. W., Cook, E. H., Cassin, B. J., & Watson, S. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.793 · Cited by 76
Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse
Maurer, H. H. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181eea318 · Cited by 74
Villalobos, C. A., Bull, P., Sáez‐Briones, P., Cassels, B. K., & Huidobro-Toro, J. P. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705722 · Cited by 61
Theobald, D. S., & Maurer, H. H. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.022 · Cited by 59 · cited 3×
“MAO-A and MAO-B are the major enzymes involved in the deamination of 2Cs [22].”
BackgroundManagement of "bad trips" in an evolving drug scene.
Taylor, R. L., Maurer, J., & Tinklenberg, J. (1970) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.1970.03170290018003 · Cited by 58
Johnson, M. P., Mathis, C. A., Shulgin, A. T., Hoffman, A. J., & Nichols, D. E. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90228-a · Cited by 57
The Emergency Department Experience with Prehospital Ketamine: A Case Series of 13 Patients
Burnett, A., Salzman, J. G., Griffith, K. R., Kroeger, B., & Frascone, R. J. (2012) · Prehospital Emergency Care · doi:10.3109/10903127.2012.695434 · Cited by 54 · cited 1×
“suggest ketamine as an alternative chemical restraint agent for patients in excited delirium, and they are not alone in this suggestion [52, 53].”
BackgroundSelf-citationTheobald, D. S., Pütz, M., Schneider, E., & Maurer, H. H. (2006) · Journal of Mass Spectrometry · doi:10.1002/jms.1045 · Cited by 51
2C‐T‐4 intoxication: Acute psychosis caused by a designer drug
Miyajima, M., Matsumoto, T., & Ito, S. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01764.x · Cited by 44 · cited 1×
“40-year-old male [42] Vanilla aroma Delirium, incoherent Treated with neuroleptic, symptoms resolved after 17 h Confirmed as 2-(2,5dimethoxy-4isopropylsulfanylphenyl)ethanamine (2C-T-4)”
BackgroundPersistent psychosis after ingestion of a single tablet of ‘2C-B’
Huang, H.-H., & Bai, Y. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.018 · Cited by 36 · cited 1×
“27-year-old male [43] 2C-B used 2 days prior to effects Acute psychosis/ hallucinations/ paranoid delusions Onset of symptoms not consistent with pharmacokinetics of 2C-B.”
Spain, D. J., Crilly, J. L., Whyte, I. M., Jenner, L., Carr, V., & Baker, A. (2008) · Emergency Medicine Australasia · doi:10.1111/j.1742-6723.2008.01066.x · Cited by 34 · cited 1×
“Benzodiazepines can be used to treat agitation, hypertension, tachycardia, and hyperthermia [44, 45].”
BackgroundStaley, J. K., Talbot, J. Z., Ciliax, B. J., Miller, G. W., Levey, A. I., Kung, M., Kung, H. F., & Mash, D. C. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01196-1 · Cited by 33 · cited 1×
“Chronic cocaine use may cause abnormal dopamine processing in the mesolimbic pathway, resulting in hyperactivity and hyperthermia [28, 29].”
BackgroundSpecial Section: Safety in EMS
Brice, J. H., & Patterson, P. D. (2012) · Prehospital Emergency Care · doi:10.3109/10903127.2011.627108 · Cited by 16
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Szabo, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00358 · Cited by 150
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.033 · Cited by 58
Metadata
- Authors
- Dean, B. V., Stellpflug, S. J., Burnett, A. M., & Engebretsen, K. M.
- Venue
- Journal of Medical Toxicology
- Published
- 2013-03-15
- Volume
- 9
- Issue
- 2
- Pages
- 172-178
- ISSN
- 1556-9039 (ISSN-L)
- 1937-6995
- OpenAlex
- W2033952955
- Cited by
- 204
- References
- 29
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.